Αποτελέσματα Αναζήτησης
15 Ιουν 2023 · 9. Treatment. IL-23 and IL-12 are cytokines that cause inflammation and encourage naive CD4+ precursor T cells to develop into T-helper 1 and T-helper 17 cells. Blocking these cytokines has recently become a promising treatment option for inflammatory bowel disease .
27 Νοε 2013 · Our results reveal an explicit role for IL-23-mediated initiation of gut tumorigenesis and implicate a key role for IL-23R+ ILC3 in the absence of overt cellular infiltrate recruitment.
11 Μαΐ 2022 · The interleukin-23 [IL-23] cytokine, derived predominantly from macrophages and dendritic cells in response to microbial stimulation, has emerged as a critical promoter of chronic intestinal inflammation.
20 Οκτ 2021 · IL-23 can induce inflammation in the gut, skin and joints in a remarkably efficient manner. Indeed, IL-23 alone can directly, rapidly and reproducibly induce the hallmark clinical features of human psoriasis [9] and PsA in mice [11].
10 Μαΐ 2006 · To explore the role of IL-23 in tumour susceptibility, we examined the expression of inflammatory immune cell products in carcinogen-treated skin. IL-23 is known to modulate the homeostasis...
5 Σεπ 2012 · IL-23 as a therapeutic intervention point. Blockade of IL-23 in the clinical setting is now receiving substantial attention after the rapid accumulation of studies highlighting the essential role of IL-23 in so many animal models of inflammation.
2 Ιουν 2023 · Targeting IL-12/23 is effective for the treatment of both moderate-to-severe Crohn’s disease and ulcerative colitis, and ustekinumab (an IL-12/23p40 antagonist) is approved for both indications.
